Share on Facebook
Share on Twitter
Share on LinkedIn
Share on Reddit
Share by Email
Print
美女免费一级视频在线观看
Deals:
Royalty Pharma announced a $2 billion funding arrangement with Revolution Medicines.
Kymera Therapeutics shrugged off a setback with Sanofi by announcing a $750 million deal with Gilead Sciences.
Novartis has promised to pay up to $750 million per target in a deal with Flagship Pioneering’s ProFound Therapeutics.
Bavarian Nordic has reached an agreement to sell a priority review voucher gained from Vimkunya’s approval to an unnamed buyer for $160 million.
Thermo Fisher Scientific was awarded a $94.5 million U.S. government contract to supply the Navy with advanced radiation detection systems
Vertex Pharmaceuticals and Ono Pharmaceutical signed a strategic agreement to develop and commercialize povetacicept in Japan and South Korea.
Adial Pharmaceuticals announced agreements with Cambrex and Thermo Fisher Scientific.
FDA:
The FDA approved Gilead Sciences’ new medicine, lenacapavir, a long-acting antiviral that treats HIV.
The agency approved Daiichi Sanyo and AstraZeneca’s Datroway for patients with previously treated advanced EGFR-mutated non-small cell lung cancer.
Syndax Pharmaceuticals received an FDA priority review of sNDA for Revuforj (revumenib) in relapsed or refractory mNPM1 acute myeloid leukemia.
The FDA is investigating the deaths from liver failure of two boys with Duchenne muscular dystrophy who were treated with Septa Therapeutics‘ gene therapy, Elevidys.
Sanofi’s Riliprubart earned an orphan drug designation for antibody-mediated rejection in solid organ transplantation
Funding rounds:
Abridge announced its $300 million Series E raise, led by Andreessen Horowitz and joined by Khosla Ventures.
Regeneron Pharmaceuticals launched a matching program for donations to the nonprofit charity Good Days to support its Retinal Vascular and Neovascular Disease Fund. The drugmaker committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the calendar year.
Commure raised $200 million in growth financing.
Vor Bio announced a $175 million private placement.
Neuron23 announced the closing of a $96.5 million Series D financing round.
San Francisco startup Centivax raised $45 million to further develop its lead drug, a universal flu vaccine.
Candel Therapeutics announced a $15 million registered direct offering of common stock.
Sunshine Biopharma closed an $8 million private placement.
Shuttle Pharmaceuticals closed a $4.25 million private placement.
Priothera secured €1.7 million in i-nov funding.
Everfront Biotech filed for a proposed initial public offering.
Layoffs:
Leap Therapeutics laid off 75% of its staff.
BlueRock Therapeutics is laying off roughly 50 employees across all of its sites.
Prothena announced a 63% workforce reduction, likely including the 91 employees in its Dublin office.
BioNTech will close its Gaithersburg, Maryland location, laying off the 63 employees there.
Industry news:
Compass Pathways reported promising results from a Phase 3 study of its psilocybin-based drug for treatment-resistant depression, but investors were unimpressed.
One off-the-shelf stem cell therapy made by Vertex Pharmaceuticals enabled 10 of 12 people with type 1 diabetes to stop insulin injections for at least a year — while maintaining healthy blood glucose levels and avoiding severe hypoglycemia.
Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial.
Amgen intends to dose its long-acting obesity shot MariTide at a lower level in its Phase 3 than it did in Phase 2.
The National Health Service blocked access to two Alzheimer’s drugs that could slow the disease, deeming them too expensive.
Nova Nordisk ended its partnership with Hims & Hers over concerns of the company selling chapter alternatives to Wegovy.
The National Institute of Health‘s support for federal guidelines that steer the treatment of more than 1 million HIV patients in the U.S. will be phased out by next June.
The NIH has abruptly paused all further terminations of biomedical research grants.
Merck announced positive topline results from the Phase 3 Hyperion study evaluating Winrevair in adults with PAH.
The Center for Disease Control and Prevention advisory committee recommended that Americans not receive flu vaccines containing thimerosal.
Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.
Biogen announced it will be advancing salanersen to a Phase 3 trial.
The Supreme Court ruled for South Carolina over its effort to defund Planned Parenthood, concluding that individual Medicaid patients cannot sue to enforce their right to pick a medical provider.
Johnson & Johnson’s Imaavy showed sustained disease control in myasthenia gravis study.
Nektar Therapeutics said its embattled immune drug rezpeg significantly improved skin clearance rates in patients with atopic dermatitis, achieving the goals of a Phase 2 study.
Opella achieved B Corp Certification.
Pfizer‘s hemophilia drug Hympavzi notched a Phase 3 win.
Syneos Health Communications, a 2025 MM+M Agency 100 honoree, launched its Empathy Engine.
Ocular Therapeutix unveiled new corporate branding.
Roche is moving its next-generation hemophilia A treatment into Phase 3 testing next year after seeing the early-stage data.
Nuvalent said that new data indicate its targeted drug zidesamtinib could help patients with a rare form of lung cancer that has failed other targeted treatments.
The Trump administration has terminated millions worth of funding for Springer Nature, a German-owned scientific publishing giant.
Altimmune announced disappointing results from a study of its GLP-1/glucagon targeted drug in MASH.
The American Medical Association and 79 leading medical societies reaffirm their support for vaccination as the best way to protect against the flu, COVID-19, and RSV and their potentially serious complications.
A presentation slated to be shared at the meeting of vaccine advisers to the CDC claimed that a study in animals suggested that use of the vaccine preservative thimerosal can have “long-term consequences in the brain” – but the study doesn’t appear to exist.
